TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative
Brief Summary: The aim of this study is to compare the efficacy, tolerability, acceptance and compliance of a PEG-only formulation compared to a reference PEG-EL formulation in resolving faecal impaction and in the treatment of chronic constipation


Options:
A: Inclusion Criteria:

* Childhood functional constipation
* 6 months to \<16 years of age
* Male or female
* For females of childbearing potential (after menarche): negative pregnancy test
* Moderately severe to severe constipation, defined as stool frequency \<3 stools/week
* Informed consent signed by parent(s) or legal acceptable representative(s), after sufficient oral and written information before entering the study, to be documented by the investigators in the Case Report Form

Exclusion Criteria:

* Functional non-retentive fecal incontinence
* Known metabolic or endocrine disorders (s.a. hypothyroidism)
* Neurologic disorders (s.a. spina bifida or spinal cord anomaly)
* Hirschsprung's disease (congenital megacolon)
* Anal anomaly
* Gastrointestinal surgery
* Drug induced constipation
* Mental retardation
* Cerebral palsy
* Treatment with other laxatives
* Drugs influencing gastrointestinal function (e.g., cisapride, erythromicin, imodium)
* Prior bowel surgery, except appendectomy
* Earlier participation in this trial
* Concurrent participation in any other clinical trial
* Participation in any other clinical study 6 months prior to inclusion
* Any use of a Macrogol within 2 months prior to inclusion
B: Inclusion Criteria:

* age 1 - 18 age
* functional constipation according to the Rome III Criteria
* consent of parents or guardians of the child to participate and study

Exclusion Criteria:

* organic cause constipation (including surgeries within the lower GI tract)
C: Inclusion Criteria:

* out-patients children with diagnosis of functional constipation or have faecal impaction on medical history and physical examination

Exclusion Criteria:

* children with organic causes for defecation disorders, such as Hirschsprung disease, spina bifid, hypothyroidism, or other metabolic or renal abnormalities;
* Children receiving medication influencing gastrointestinal motility;
* Children with suspected gastrointestinal obstruction or stenosis
D: Inclusion Criteria:

* Chronic constipation (defined as at least 3 months of less than 2 bowel movements (BMs) per week and/or one of the following symptoms : hard stool, painful defecation, encopresis)
* Constipation previously treated by dietary advice (high fiber diet) for at least two weeks without efficacy

Exclusion Criteria:

* Organic bowel diseases
* Suspected GI obstruction
* History of GI surgery

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The main hypothesis of the study is that anaesthesia of the hip using infiltration with a local anesthetic solution is preferable over traditional analgesia with oral opioid medications in the acute stage of the management of patients with a fracture of the hip.

To study the hypothesis the investigators designed a prospective randomised study where patients are assigned in two groups, the first receiving local hip anesthesia and the other placebo treatment. Both groups are eligible to use of standard oral pain treatment.

Effect of analgesia as well as medical complications will be recorded.


Options:
A: Inclusion Criteria:

- patients with femoral neck fracture in the emergency department

Exclusion Criteria:

* presence of demencia
* body weight less than 40kg
* presence of a cancer or patients receiving chemotherapy
* allergy to local anaesthetics
B: Inclusion criteria (must meet all 3):

* Greater than or equal to 65 years
* Have a hip fracture requiring surgery
* Written informed consent for participation of study prior to surgery.

Exclusion criteria:

* Contraindication to peripheral nerve block or local anaesthetics
* Unable to do delirium or cognitive testing due to language, vision or hearing impairment
* Unable to communicate with research staff due to language barriers
* History of chronic opioid use (longer than 1 month)
* Contraindication to general anesthesia
C: Inclusion Criteria:

* fracture of the hip

Exclusion Criteria:

* multiple fractures,
* delay (more than 12 hours) from the time of injury until admission to the hospital,
* local infections, hypersensitivity to local analgetics,
* cognitive impairment
D: Inclusion Criteria:

* Age 55 or older
* Sustaining either an OTA/AO type 31A or 31B fracture undergoing ORIF or hemiarthroplasty
* Able to consent
* Isolated injury

Exclusion Criteria:

* OTA/AO 31B1 (Impacted/slightly displaced)
* Baseline dementia or cognitive deficit
* Inability to consent
* Chronic Opioid use
* End stage liver disease with Model for End-Stage Liver Disease (MELD) greater than 20.
* End stage renal disease as defined by patients requiring hemodialysis at least twice weekly
* Polytrauma, defined as: concurrent upper or lower extremity fracture, pelvis fracture, spine fracture, rib fractures, or facial fractures, Blunt chest or abdominal trauma resulting in diagnosed organ injury, Head trauma resulting in intracranial bleed or diagnosed concussion
* Allergy to amide-type local anesthetics
* Prisoners (unlikely to be accessible for follow-up)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integration of Small-scale Aquaculture With Homestead Food Production for Improved Household Food Security and Nutrition in Rural Cambodia
Brief Summary: The project is a three arm randomized control trial in rural Cambodia designed to evaluate the impact of homestead food production (home gardens) with and without fish ponds versus control on household food security, dietary intake of women and youngest child, biochemical nutritional status of women, and household livelihoods over a 22 month period. Baseline and end line surveys will be conducted that involve questionnaires and a blood sample.


Options:
A: Inclusion Criteria:

* Poor or very poor household (HEA criteria)
* Having at least one children under 1 year old at the time of inclusion

Exclusion Criteria:

* Medium or rich economic status (HEA criteria)
* no child under one year old at the time of inclusion
* not living in one of the 32 selected villages in the Tapoa province
B: Inclusion Criteria:

* Must be represented by a woman.
* Must fall within the "poor" category in terms of community wealth rankings.
* Must have access to land (including homestead) for agriculture cultivation.
* Must have sufficient access to labor to undertake the homestead production activities.
* Must have a keen interest in participating in this action.
* Must have a least one child less than five years of age (in 80% of the target households).
* Have suitable land for pond and preferably own a small pond

In addition village model farm owners will:

* Have at least 1,200 square meters of land that can be used to establish the model farm;
* Have some disposable income to invest in the model farm for fencing and land preparation;
* Be productive, open to new ideas and willing to provide assistance to other households in the village;
* Be able and willing to maintain the VMF throughout the year;
* Commit to providing inputs and marketing support to group members at least during the project.

Exclusion Criteria:

* None, only that they don't meet the inclusion criteria
C: Inclusion Criteria:

* female
* 13-22 years old
* never married
D: Inclusion Criteria:

* Households with residential or mailing address in Hampden County, Massachusetts
* Receiving SNAP benefits in July 2011

Exclusion Criteria:

* Child-only cases (households not including at least one member aged 16 or older eligible to serve as SNAP head of household)
* Cases with benefits signed over to residential or treatment facilities

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Stages of Change Through the Cardiac Rehabilitation Experience After a Recent Hospitalization
Brief Summary: The purpose of this study is to test if an early appointment (within 10 days) when compared to a standard appointment (5 weeks) will affect attendance at the Cardiac Rehabilitation orientation and subsequent enrollment into cardiac rehabilitation.


Options:
A: Inclusion Criteria (patients): Men and women who

* are having first-time non-emergency CABG surgery
* are judged ready for discharge
* are being discharged to home \[either their own or to family/friends\]
* have access to and are able to communicate over a telephone
* are able to read, write and understand English

Inclusion Criteria (peers): Men and women who

* have undergone CABG surgery within the last 5 years
* have access to and are able to communicate clearly over a telephone
* are able to read, write and understand English
* have attended a formal cardiac rehabilitation program
* are not associated with the current in-hospital peer volunteer program
B: Inclusion Criteria:

* Being within the age-range of 45 to 85 years old
* having the minimum literacy for reading and writing
* being hospitalized due to MI for the first time
* verification of MI by clinical symptoms
* enzyme-serum tests and cardiograph changes
* lack of participation in the any related educational course simultaneously with the execution of intervention
* patients' willingness toward participating in the research
* having no psychological problems
* ability to fill out the questionnaire and participating in the empowerment program.

Exclusion Criteria:

* any offending items from mentioned criteria.
C: Inclusion Criteria:

* ICD implanted in the 12 months prior to study entry
* Currently taking beta blocker medication
* Speaks and reads English

Exclusion Criteria:

* Unstable angina, heart attack, or percutaneous coronary intervention (PCI) in the 3 months prior to study entry
* Experienced an ICD shock in the 3 months prior to study entry
* Currently exercises 3 times a week for 20 minutes a day
* Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score for alcohol consumption greater than 4
* Shore Blessed score for cognitive dysfunction greater than 6
D: Inclusion Criteria:

* Stable Angina
* Myocardial infarction
* Percutaneous coronary intervention
* willingness to participate and consent for medical record review
* willingness to complete survey's

Exclusion Criteria:

* Recent illicit drug use
* Unstable psychiatric condition
* Moderate or severe dementia
* Inability to follow-up
* Leaving system with plans to enroll in cardiac rehabilitation out-of-system
* Inability to exercise (amputee, severe claudication)
* Unstable medical condition that would prevent regular exercise training
* Uncorrected severe aortic stenosis or severe mitral stenosis
* Referring physician feels that exercise is contra-indicated due to safety or other patient specific factors
* CABG, LVAD, or Heart Transplant

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)
Brief Summary: On the basis of published data and the investigators' results indicating that oxidative stress may contribute to the peripheral skeletal muscle dysfunction in patients with FSHD, the investigators propose a study to test whether or not an antioxidant supplementation has a therapeutic interest for patients with FSHD. Their results have important implications for the successful implementation of rational antioxidant therapy in FSHD in which cell loss could be linked to oxidative stress.


Options:
A: Inclusion Criteria:

a) recreationally trained as evidenced by their maximal oxygen consumption levels (VO2max \>45 ml/kg/min), b) were engaged in systematic exercise at least three times/week for ≥12 months), c) non-smokers, d) abstained from any vigorous physical activity during the study, e)abstained from consumption of caffeine, alcohol, performance-enhancing or antioxidant supplements, and medications during the study.

Exclusion Criteria:

a) a known NAC intolerance or allergy, b) a recent febrile illness, c) history of muscle lesion, d) lower limb trauma
B: Inclusion Criteria:

* trained at least five sessions per week with 90 to 120 min per session
* had an experience of more than 3 years in Olympic weightlifting

Exclusion Criteria:

* use any antioxidant (e.g., vitamin E, A, C etc..) or anti-inflammatory during the experimentation period and one month before
* had injuries during the experimentation period and one month before
C: Inclusion Criteria:

* Must be able to swallow tablets
* signed informed consent
* no concommitant medication
* male
* age between 25 - 35 years

Exclusion Criteria:

* drug, tobacco or alcohol abuse
* any chronic disease
* any acute or chronic inflammatory disease as determined by a leucocyte count \> 7000 Gpt/l, C-reactive protein (CrP) \> 5.0 mg/dl or clinical signs of infection
* systolic blood pressure (SBP) \> 140mmHg and diastolic blood pressure (DBP) was \> 85mmHg
* cardiovascular or peripheral artery disease
* thyroid dysfunction
D: Inclusion Criteria:

* FSHD patients will be recruited on the basis of:

  * The number of repeat units (4 to 9)
  * FSHD patients with a positive family history for FSHD
  * Not confined to a wheelchair
  * No smokers
  * No associated co-morbidity (cardiac or pulmonary disease, diabetes etc.)
  * No Medications or nutritional supplementation (vitamins and/or antioxidants) at the time of the study
  * No HIV positive

Exclusion Criteria:

* No consent form

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The study compares the Veress needle technique, the Direct trocar insertion and the Open technique with each other, in terms of minor complications, in elective laparoscopic procedures for benign pathologies.


Options:
A: Inclusion Criteria:

1. Suspected acute appendicitis on clinical and radiographic (CT) grounds

Exclusion Criteria:

1. Phlegmon, mass, peri-appendicecal abscess, or diffuse peritonitis
2. Prior open laparotomy with incision through the umbilicus
3. Body Mass Index \> 35
4. Age \<18 years
5. Mental illness, dementia, or inability to provide informed consent
6. Chronic pain requiring daily medication (including opiate and NSAIDs)
7. Pregnancy
8. Alternative diagnosis found by diagnostic laparoscopy (post-randomization)
B: Inclusion Criteria:

* not-obese adult patients referred for scheduled laparoscopic and gynecologic procedures,
* benign pathology
* no previous abdominal surgery
* Age range was 18-70 years

Exclusion Criteria:

* obesity, defined as a body mass index (BMI) \> 30 kg/m2
* previous abdominal surgery by laparoscopy or laparotomy
* history of PID
* irritable Bowel Syndrome
* suspicion of malignancy or malignancy at the histological examination
C: Inclusion Criteria:

* Biliary cholic
* Biliary dyskinesia
* Gallbladder polyps
* Other diagnosis at the discretion of the surgeon

Exclusion Criteria:

* History of Acute cholecystitis
* Jaundice
* Choledocolithiasis
* History of Pancreatitis
* Severe comorbidity
* BMI \> 30
D: Inclusion Criteria:

* patients with palpable varicoceles

Exclusion Criteria:

* unfit for anesthesia or laparoscopy

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial
Brief Summary: The study hypothesis states that giving early enteral Vitamin D supplementation to preterm infants will decrease respiratory morbidity in extremely preterm infants.


Options:
A: Inclusion Criteria:

* Infants admitted to the Regional Newborn ICU of the University of Alabama with gestational age between 23-27 completed weeks

Exclusion Criteria:

* Major congenital/chromosomal anomalies
* Moribund infant with low likelihood of survival, in opinion of the clinical team
B: Inclusion Criteria:

* age 1-5 years
* physician-diagnosed asthma as per the Global Initiative for Asthma (GINA) guidelines
* URTIs as the main asthma trigger (parental report)
* ≥4 URTIs in the past 12 months (parental report)
* ≥1 asthma exacerbation requiring rescue oral corticosteroids (OCS) in the past 6 months or ≥2 in the past 12 months

Exclusion Criteria:

* intake or intention to use more than 400 IU/day of vitamin D supplement
* extreme prematurity (\<28 weeks gestation)
* infants \<12 months of age
* no vitamin D supplementation when breast-fed
* recent (\<1 year) immigrants from a region at high risk of rickets
* children with vitamin D restrictive diets e.g. vegans
* other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis)
* condition(s) that alter calcium or vitamin D metabolism/absorption (hypo/hyperparathyroidism, kidney/liver disease, inflammatory bowel disease)
* medications that interfere with vitamin D metabolism (anti-epileptics, diuretics, antacids, anti-fungal drug)
* vitamin D supplementation \>1000 IU/ day in last 3 months
* anticipated difficult follow-up (unable to attend clinic visits; plan to leave the province).
C: Inclusion Criteria:

* Preterm infants with gestational age 24 to 32 weeks who achieved at least 75% of total nutrition by enteral feedings in postnatal 2 weeks

Exclusion Criteria:

* perinatal asphyxia,
* major congenital or chromosomal anomalies,
* those with no expectation of survival in first 2 weeks
* those that total parenteral nutrition was not ceased by the first 2 weeks
D: Inclusion Criteria:

* Healthy singleton newborn infants born at term age of any racial background.
* Infants may be breastfed or formula fed during the study as is safe since the supplement is 400 IU/d and intakes from breast milk or formula will not exceed 400 IU/d for a theoretical total intake of 800 IU/d that is recommended by the Canadian Pediatric Society.

Exclusion Criteria:

* Infants born prematurely, twins or other multiples.
* Unable to nurse or accept the supplement.
* Congenital malformations.
* Parents not fluent enough in English or French to provide written informed consent.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
Brief Summary: Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin.

Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.


Options:
A: Inclusion Criteria:

* primary atonic postpartum hemorrhage after vaginal delivery

Exclusion Criteria:

* Patients who delivered by caesarean section
* Retained placenta
* Traumatic postpartum hemorrhage
* Associated coagulopathy
* Chronic medical illness (hepatic , renal diseases)
* Refusal to participate in the study.
B: Inclusion Criteria:

* Women must be pregnant
* Must be able to provide informed consent
* Must agree to have a community health worker present at the time of delivery
* Must agree to participate in a follow up interview by the study midwife
* Must agree to have pre and postpartum haemoglobin taken

Exclusion Criteria:

* Women who do not meet the inclusion criteria
C: Inclusion Criteria:

* Women with atonic PPH.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Hypertension.
* Preeclampsia.
* Cardiac, renal or liver diseases
* Epilepsy.
* Known hypersensitivity to Carbetocin
D: Inclusion Criteria:

* Atonic PPH

Exclusion Criteria:

* Gestational age\<37 weeks
* Hypertension, cardiac disease or preeclampsia

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Study of Two Injection Techniques Added to Proven Strategies to Reduce Pain in One- to Twelve-month Old Infants Undergoing Immunization
Brief Summary: Immunization injections are a significant source of pain for infants. Tactile stimulation (rubbing/applying pressure) may be an effective and feasible pain-relieving intervention - it is cost neutral, and has been shown to be effective in children and adults undergoing injections. The aim of this study is to determine the added benefit of tactile stimulation when added to other proven analgesic interventions during routine infant immunization injections.


Options:
A: Inclusion Criteria:

1. Healthy infants undergoing vaccination.

Exclusion Criteria:

1. preterm birth (\<37 weeks gestation)
2. prior hospitalization/surgery (other than postnatal care),
3. documented/ suspected sensitivity/allergy to amide anaesthetics/vaccines,
4. mother plans to breastfeed or to use topical anesthetics or sugar water during injection.
B: Inclusion Criteria:

* normal full-term newborns (\>38 weeks)
* Apgar score \>=8 at five minutes after delivery.

Exclusion Criteria:

* congenital anomalies
* medical complications
* need for oxygen administration
C: Inclusion Criteria:

* Healthy infant
* 2 - 6 months of age
* receiving primary DPT and PCV vaccinations

Exclusion Criteria:

* chronic illness
* immune deficiency
* immunosuppression
* a history of allergy to DPT or PCV or any of its components
* fever
* any acute illness that prevents the administration of the vaccine
D: Inclusion Criteria:

* infants 1-12 months of age receiving routine immunization injections in an outpatient pediatric clinic in Toronto

Exclusion Criteria:

* impaired neurological development
* history of seizure
* use of topical anesthetics
* use of sedatives or narcotics within 24 hours
* fever or illness that would prevent administration of vaccine
* prior participation in the trial

Answer: D